New Two-Pronged attack on HPV cancers tested in early trial
NCT ID NCT04432597
Summary
This early-stage trial is testing a new therapeutic vaccine designed to fight cancers caused by the human papillomavirus (HPV). Researchers want to see if the vaccine works better when given alone or combined with an immunotherapy drug called M7824. The study includes adults with various advanced or newly diagnosed HPV-positive cancers to find a safe dose and see if the treatments can stimulate the immune system to attack the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.